AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: OCGN
Report Date: 2026-05-05
Full Report: https://amaly.io/stock/OCGN

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: Ocugen, Inc. (OCGN) is a clinical-stage biopharmaceutical company in the Biotechnology sector focused on gene therapies for blindness diseases. Its core business activities are Shariah-compliant, emphasizing medical innovation for unmet needs. However, the financial screening reveals a critical failure in the interest income ratio at 111.72%, far exceeding the 5% threshold across all standards, driven by low revenue and interest-bearing cash holdings. Debt and liquidity ratios are strong at 10.41% and 12.37%, respectively. The company is not included in any major Shariah indices, leading to an overall NON_COMPLIANT status with a B quality rating.

Primary Compliance Concerns:
- Interest Income Ratio: 111.72% (threshold: 5%)
- High reliance on interest-bearing instruments in low-revenue environment

Purification Requirement: 111.72%
Index Inclusion: Not included in any major Shariah indices (S&P, MSCI, FTSE, DJIM).

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 10.4%
Liquidity Ratio: 12.4%
Interest Income Ratio: 111.7%
Purification Required: 11.72%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2026-02-28

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-04-02T10:00:00Z

---
Full interactive report: https://amaly.io/stock/OCGN
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.